Why Sarepta Therapeutics Stock Faded This Week
Shares of the rare disease juggernaut Sarepta Therapeutics (NASDAQ: SRPT) fell by 12.6% through the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The biotech's stock fell almost on cue ahead of the upcoming advisory committee meeting this Friday for its Duchenne muscular dystrophy (DMD) gene therapy known as SRP-9001. It's almost tradition at this point for smaller companies with high-value product candidates to dip ahead of an advisory committee meeting.